Increasing chemical diversity to overcome the pharmacokinetic limitations of Aptamers

In 2004, the first and so far only therapeutic aptamer, pegaptanib for the treatment of neovascular (wet) age-related macular degeneration, was approved by the FDA. Since then, only a small number of therapeutic aptamers have entered clinical trials, largely because potential applications have been limited by the inherent physicochemical properties and ensuing pharmacokinetic profile of…